China SXT Pharmaceuticals, Inc.

SXTC

VGG2161P1403

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:30:00 31/05/2024 BST			5-day change	1st Jan Change
1.05 ^USD	-8.64%		-1.83%	-73.54%

05-13	China SXT Pharmaceuticals, Inc. announced that it has received $0.75 million in funding from Streeterville Capital, LLC	CI
05-09	China SXT Pharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding from Streeterville Capital, LLC	CI

China Sxt Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2019

April 22, 2020 at 09:39 pm

China SXT Pharmaceuticals, Inc. announced earnings results for the half year ended September 30, 2019. For the half year, the company announced total revenue was USD 3.215 million compared to USD 3.917 million a year ago. Operating loss was USD 220,753 compared to operating Income of USD 1.326 million a year ago. Net loss was USD 2.348 million compared to net income of USD 995,046 a year ago. Basic loss per share from continuing operations was USD 0.1 compared to basic earnings per share from continuing operations of USD 0.05 a year ago.

Latest news about China SXT Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc. announced that it has received $0.75 million in funding from Streeterville Capital, LLC	05-12	CI
China SXT Pharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding from Streeterville Capital, LLC	05-08	CI
China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	04-05	CI
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	02-08	MT
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	02-08	MT
Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data	01-02	MT
US Equity Futures Set Kick Off 2024 Lower Ahead of Manufacturing PMI, Construction Data	01-02	MT
China SXT Pharmaceuticals to Implement 1-for-25 Reverse Stock Split	04/10/23	MT
China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	31/07/23	CI
China SXT Pharmaceuticals, Inc. announced that it has received $2 million in funding from Streeterville Capital, LLC	06/03/23	CI
China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2022	24/02/23	CI
China SXT Pharmaceuticals, Inc. announced that it has received $1.5 million in funding from Streeterville Capital, LLC	19/12/22	CI
China SXT Pharmaceuticals, Inc. announced that it expects to receive $1.5 million in funding from Streeterville Capital, LLC	18/12/22	CI
Top Premarket Gainers	05/12/22	MT
China SXT Pharmaceuticals, Inc. announced that it has received $2.194827 million in funding	21/09/22	CI
China SXT Pharmaceuticals, Inc. announced that it expects to receive $2.194827 million in funding	21/09/22	CI
China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	18/07/22	CI
China SXT Pharmaceuticals Effects 1-for-20 Reverse Stock Split; Shares Decline	18/05/22	MT
China SXT Pharmaceuticals, Inc. Announces Resignation of Jingzhen Deng as Chief Scientific Officer and Chief Operation Officer	11/05/22	CI
Top Premarket Gainers	29/03/22	MT
China SXT Pharmaceuticals Agrees to Issue $2.8 Million of Convertible Promissory Notes to Streeterville Capital	15/03/22	MT
China SXT Pharmaceuticals, Inc. Announces Executive Changes	31/01/22	CI
Health Care Fall Tuesday But Resist Steepest Declines	18/01/22	MT
Sector Update: Health Care	18/01/22	MT
Top Midday Decliners	18/01/22	MT

Chart China SXT Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

China SXT Pharmaceuticals Inc is a China-based pharmaceutical company that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). The Company develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The Company sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHINA SXT PHARMACEUTICALS, INC.	-73.54%	765K
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+31.16%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+14.74%	240B
NOVARTIS AG	+9.47%	210B
ROCHE HOLDING AG	-5.19%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals